165 related articles for article (PubMed ID: 7858269)
41. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
42. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia.
Leahey AM; Teunissen H; Friedman DL; Moshang T; Lange BJ; Meadows AT
Med Pediatr Oncol; 1999 Mar; 32(3):163-9. PubMed ID: 10064182
[TBL] [Abstract][Full Text] [Related]
43. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Matsue K; Tohi T; Masauji N; Tsukuda K
Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
[TBL] [Abstract][Full Text] [Related]
44. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission.
Woods WG; Neudorf S; Gold S; Sanders J; Buckley JD; Barnard DR; Dusenbery K; DeSwarte J; Arthur DC; Lange BJ; Kobrinsky NL;
Blood; 2001 Jan; 97(1):56-62. PubMed ID: 11133742
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY
Blood; 1995 Apr; 85(8):2263-8. PubMed ID: 7718899
[TBL] [Abstract][Full Text] [Related]
46. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Michel G; Gluckman E; Esperou-Bourdeau H; Reiffers J; Pico JL; Bordigoni P; Thuret I; Blaise D; Bernaudin F; Jouet JP
J Clin Oncol; 1994 Jun; 12(6):1217-22. PubMed ID: 8201385
[TBL] [Abstract][Full Text] [Related]
48. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
Linker CA; Ries CA; Damon LE; Rugo HS; Wolf JL
Bone Marrow Transplant; 1998 Nov; 22(9):865-72. PubMed ID: 9827814
[TBL] [Abstract][Full Text] [Related]
49. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
[TBL] [Abstract][Full Text] [Related]
50. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
Jourdan E; Maraninchi D; Reiffers J; Gluckman E; Rio B; Jouet JP; Michallet M; Molina L; Archimbaud E; Harousseau JL; Ifrah N; Attal M; Guilhot F; Kuentz M; Guyotat D; Pico JL; Dauriac C; Legros M; Dreyfus F; Bordigoni P; Leblond V; Gratecos N; Varet B; Auzanneau C; Blaise D
Bone Marrow Transplant; 1997 May; 19(9):875-81. PubMed ID: 9156260
[TBL] [Abstract][Full Text] [Related]
51. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate.
Zikos P; Van Lint MT; Frassoni F; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; De Stefano F; Soracco M; Vitale V; Bacigalupo A
Blood; 1998 May; 91(9):3503-8. PubMed ID: 9558411
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey T; Clift RA
J Clin Oncol; 1996 Jan; 14(1):220-6. PubMed ID: 8558201
[TBL] [Abstract][Full Text] [Related]
53. Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Blume KG; Long GD; Negrin RS; Chao NJ; Kusnierz-Glaz C; Amylon MD
Bone Marrow Transplant; 1994; 14 Suppl 4():S9-10. PubMed ID: 7728133
[TBL] [Abstract][Full Text] [Related]
54. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
Zecca M; Pession A; Messina C; Bonetti F; Favre C; Prete A; Cesaro S; Porta F; Mazzarino I; Giorgiani G; Rondelli R; Locatelli F
J Clin Oncol; 1999 Jun; 17(6):1838-46. PubMed ID: 10561223
[TBL] [Abstract][Full Text] [Related]
55. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
56. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis.
Gupta T; Kannan S; Dantkale V; Laskar S
Hematol Oncol Stem Cell Ther; 2011; 4(1):17-29. PubMed ID: 21460603
[TBL] [Abstract][Full Text] [Related]
57. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385
[TBL] [Abstract][Full Text] [Related]
58. Fractionated total body irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission.
Snyder DS; Findley DO; Forman SJ; Nademanee AP; O'Donnell MR; Schmidt GM; Bierman PJ; Fahey JL; Krance RA; Sniecinski IJ
Blut; 1988 Jul; 57(1):7-13. PubMed ID: 3291991
[TBL] [Abstract][Full Text] [Related]
59. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
60. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
